Bliss GVS Pharma starting a rally!Bliss GVS Pharma LimitedNSE_DLY:BLISSGVSgarv_sk9A Multi‑year technical breakout, and sustained momentum in the pharma export cycle. Bliss GVS operates across India and international markets, manufacturing a wide range of formulations including tablets, capsules, injectables, gels, suspensions, and more. This diversification reduces concentration risk and positions the company well for global tender‑based demand. BLISSGVS is in a powerful uptrend backed by strong earnings growth, a clean balance sheet, attractive valuation vs peers, and technical confirmation of a multi‑year breakout. For traders, the combination of momentum + fundamentals + sector tailwinds makes it a compelling long candidate. Export‑oriented Indian pharma companies typically benefit from: Currency tailwinds Global tender wins Lower-cost manufacturing advantage BLISSGVS fits this profile. == Performance == The stock has delivered 108–119% returns in the past 1 year, reflecting strong institutional accumulation and trend strength. It is trading near fresh all‑time highs after a successful multi‑year breakout, with price retesting and bouncing from prior resistance—now acting as support. == Technical analysts highlight == - Price above all major EMAs on daily & weekly charts - Bollinger Band expansion indicating volatility expansion in the direction of the trend - Strong uptrend continuation signals Broke out with volumes == Strong Financial Trajectory == Revenue (TTM): ₹8.68B, up 7.2% YoY. Net Income: ₹1.09B, up 83% YoY — a major profitability expansion. EPS growth: +81.2% YoY, showing operational leverage kicking in.